Diabetic macular oedema: evidence-based treatment recommendations for Asian countries

被引：31

作者：

Cheung, Gemmy C. M. ^{[1
]}

Yoon, Young Hee ^{[3
]}

Chen, Lee Jen ^{[5
]}

Chen, Shih Jen ^{[6
,7
]}

George, Tara M. ^{[8
]}

Lai, Timothy Y. Y. ^{[9
]}

Park, Kyu Hyung ^{[4
]}

Tahija, Sjakon G. ^{[10
]}

Uy, Harvey S. ^{[11
]}

Wong, Tien Y. ^{[2
]}

机构：

[1] Natl Univ Singapore, Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore, Singapore

[2] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore

[3] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Coll Med, Seongnam, South Korea

[5] MacKay Mem Hosp, Taipei, Taiwan

[6] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan

[7] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan

[8] Sunway Med Ctr, Ctr Eye, Petaling Jaya, Malaysia

[9] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China

[10] Klin Mata Nusantara, Jakarta, Indonesia

[11] Univ Philippines, Dept Ophthalmol & Visual Sci, Philippine Gen Hosp, Manila, Philippines

来源：

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2018年 / 46卷 / 01期

关键词：

anti-vascular endothelial growth factor; Asia; diabetes mellitus; diabetic macular oedema; evidence-based treatment; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED CLINICAL-TRIAL; MAJOR RISK-FACTORS; INTRAVITREAL AFLIBERCEPT; FLUOCINOLONE ACETONIDE; LASER TREATMENT; DEFERRED LASER; RANIBIZUMAB TREATMENT; GLOBAL PREVALENCE; FACTOR THERAPY;

D O I：

10.1111/ceo.12999

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Diabetic macular oedema is the most common cause of diabetic retinopathy-induced vision loss. Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian-specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti-vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti-vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.

引用

页码：75 / 86

页数：12

共 70 条

[1] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
AIELLO, LP
AVERY, RL
ARRIGG, PG
KEYT, BA
JAMPEL, HD
SHAH, ST
PASQUALE, LR
THIEME, H
IWAMOTO, MA
PARK, JE
NGUYEN, HV
AIELLO, LM
FERRARA, N
KING, GL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
[2] Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema A Systematic Review and Meta-analysis
Avery, Robert L.
Gordon, Gabriel M.
[J]. JAMA OPHTHALMOLOGY, 2016, 134 (01) : 21 - 29
[3] Vascular endothelial growth factors and vascular permeability
Bates, David O.
[J]. CARDIOVASCULAR RESEARCH, 2010, 87 (02) : 262 - 271
[4] Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy Long-Term Outcomes of the Phase III RIDE and RISE Trials
Boyer, David S.
Nguyen, Quan Dong
Brown, David M.
Basu, Karen
Ehrlich, Jason S.
[J]. OPHTHALMOLOGY, 2015, 122 (12) : 2504 - +
[5] Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
Boyer, David S.
Yoon, Young Hee
Belfort, Rubens, Jr.
Bandello, Francesco
Maturi, Raj K.
Augustin, Albert J.
Li, Xiao-Yan
Cui, Harry
Hashad, Yehia
Whitcup, Scott M.
[J]. OPHTHALMOLOGY, 2014, 121 (10) : 1904 - 1914
[6] Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
Bressler, Susan B.
Ayala, Allison R.
Bressler, Neil M.
Melia, Michele
Qin, Haijing
Ferris, Frederick L., III
Flaxel, Christina J.
Friedman, Scott M.
Glassman, Adam R.
Jampol, Leem.
Rauser, Michael E.
[J]. JAMA OPHTHALMOLOGY, 2016, 134 (03) : 278 - 285
[7] Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies
Brown, David M.
Schmidt-Erfurth, Ursula
Do, Diana V.
Holz, Frank G.
Boyer, David S.
Midena, Edoardo
Heier, Jeffrey S.
Terasaki, Hiroko
Kaiser, Peter K.
Marcus, Dennis M.
Nguyen, Quan D.
Jaffe, Glenn J.
Slakter, Jason S.
Simader, Christian
Soo, Yuhwen
Schmelter, Thomas
Yancopoulos, George D.
Stahl, Neil
Vitti, Robert
Berliner, Alyson J.
Zeitz, Oliver
Metzig, Carola
Korobelnik, Jean-Francois
[J]. OPHTHALMOLOGY, 2015, 122 (10) : 2044 - 2052
[8] Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
Brown, David M.
Quan Dong Nguyen
Marcus, Dennis M.
Boyer, David S.
Patel, Sunil
Feiner, Leonard
Schlottmann, Patricio G.
Rundle, Amy Chen
Zhang, Jiameng
Rubio, Roman G.
Adamis, Anthony P.
Ehrlich, Jason S.
Hopkins, J. Jill
[J]. OPHTHALMOLOGY, 2013, 120 (10) : 2013 - 2022
[9] Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
Campochiaro, Peter A.
Brown, David M.
Pearson, Andrew
Chen, Sanford
Boyer, David
Ruiz-Moreno, Jose
Garretson, Bruce
Gupta, Amod
Hariprasad, Seenu M.
Bailey, Clare
Reichel, Elias
Soubrane, Gisele
Kapik, Barry
Billman, Kathleen
Kane, Frances E.
Green, Kenneth
[J]. OPHTHALMOLOGY, 2012, 119 (10) : 2125 - 2132
[10] Sustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal Insert
Campochiaro, Peter A.
Hafiz, Gulnar
Shah, Syed Mahmood
Bloom, Steven
Brown, David M.
Busquets, Miguel
Ciulla, Thomas
Feiner, Leonard
Sabates, Nelson
Billman, Kathleen
Kapik, Barry
Green, Ken
Kane, Frances
[J]. OPHTHALMOLOGY, 2010, 117 (07) : 1393 - U157

← 1 2 3 4 5 6 7 →